Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|HER2-positive Breast Cancer
Interventions: DRUG: ZN-A-1041 50mg BID|DRUG: ZN-A-1041 100mg BID|DRUG: ZN-A-1041 200mg BID|DRUG: ZN-A-1041 400mg BID|DRUG: ZN-A-1041 600mg BID|DRUG: ZN-A-1041 800mg BID|DRUG: ZN-A-1041 1000mg BID|DRUG: ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|DRUG: ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|DRUG: ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|DRUG: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle
Sponsor: Suzhou Zanrong Pharma Limited